Cagrilintide + Semaglutide
Amylin + GLP-1, combined.
A combined presentation of an amylin analogue and a GLP-1 agonist — two distinct satiety pathways studied together.
Purity
≥99% (HPLC)
Presentations
5 + 5 mg
Format
Research use only
Cagrilintide + Semaglutide · RD-18In research terms
How it's
understood.
Pairs amylin-receptor activation with GLP-1 signalling to investigate additive effects on appetite and metabolic parameters.
Descriptions summarise published research context only. Nothing here is dosing guidance or a claim of any effect in humans.
Where it's studied
Dual satiety-pathway models
Combination metabolic research
Comparative agonist studies
Research use only
For laboratory research. Not for human consumption.
Cagrilintide + Semaglutide is supplied to researchers and institutions for in-vitro and laboratory study. Need a certificate of analysis or handling detail for Cagrilintide + Semaglutide? Get in touch.
Request documentation →Related compounds
View all →
All products listed are supplied strictly for laboratory and research use only. They are not dietary supplements, medicines or foods, and are not intended for human or veterinary consumption, diagnosis or treatment. This website is informational and does not offer products for sale.